STAG2 mutations fine-tune the ALK-driven oncogenic program in ALK-positive anaplastic large cell lymphoma.

Loss of STAG2 accelerates early oncogenesis and alters gene expression in ALK-positive anaplastic large cell lymphoma, with 6 out of 16 mutations impairing cohesin function.

• Why it matters: Understanding genetic drivers in ALK+ ALCL is crucial due to its aggressive nature and limited known variants, which hampers targeted therapy development.
• What they did: Paired whole-exome sequencing of patient tumors identified frequent STAG2 mutations; functional studies in a primary T cell model showed STAG2 loss promotes proliferation and early tumor hallmarks.
• The result: STAG2 depletion enhances cell adhesion, migration, and immune evasion, revealing its role in early lymphomagenesis and suggesting it as a potential therapeutic target.